MA45053A - Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique - Google Patents
Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystiqueInfo
- Publication number
- MA45053A MA45053A MA045053A MA45053A MA45053A MA 45053 A MA45053 A MA 45053A MA 045053 A MA045053 A MA 045053A MA 45053 A MA45053 A MA 45053A MA 45053 A MA45053 A MA 45053A
- Authority
- MA
- Morocco
- Prior art keywords
- cystic fibrosis
- treatment
- conductance regulator
- transmembrane conductance
- polynucleotides coding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
- C12Y207/04003—Adenylate kinase (2.7.4.3)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662338492P | 2016-05-18 | 2016-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45053A true MA45053A (fr) | 2019-03-27 |
Family
ID=60325676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045053A MA45053A (fr) | 2016-05-18 | 2017-05-18 | Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique |
Country Status (4)
Country | Link |
---|---|
US (1) | US11801227B2 (fr) |
EP (1) | EP3458108A4 (fr) |
MA (1) | MA45053A (fr) |
WO (1) | WO2017201347A1 (fr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
EP3052521A1 (fr) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucléotides codant pour un récepteur de lipoprotéines de faible densité |
CA2935960C (fr) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Dispositif d'acoustophorese avec double chambre acoustophoretique |
CA3177878A1 (fr) | 2014-04-23 | 2015-10-29 | Modernatx, Inc. | Vaccins a base d'acide nucleique |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP4218805A1 (fr) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Vaccins contre les maladies infectieuses |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
HUE057613T2 (hu) | 2015-09-17 | 2022-05-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
WO2017070613A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccin contre le cytomégalovirus humain |
AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
EA201891001A1 (ru) | 2015-10-22 | 2018-11-30 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv) |
TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
WO2017099823A1 (fr) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions et procédés permettant d'administrer des agents thérapeutiques |
WO2017106799A1 (fr) | 2015-12-17 | 2017-06-22 | Modernatx, Inc. | Polynucléotides codant pour la méthylmalonyl-coa mutase |
AU2016377681B2 (en) | 2015-12-22 | 2021-05-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
MA45041A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1 |
JP7210287B2 (ja) | 2016-05-18 | 2023-01-23 | モダーナティエックス・インコーポレイテッド | Ii型シトルリン血症の治療のためのシトリンをコードするポリヌクレオチド |
CA3024500A1 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides codant la relaxine |
WO2018053209A1 (fr) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | Compositions d'arn de haute pureté et procédés pour leur préparation |
WO2018075980A1 (fr) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Vaccin contre le cytomégalovirus humain |
WO2018089540A1 (fr) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Formulations stabilisées de nanoparticules lipidiques |
CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
WO2018107088A2 (fr) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Vaccins à acide nucléique contre des virus respiratoires |
US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
WO2018151816A1 (fr) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | Compositions immunogènes très puissantes |
JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
DK3596042T3 (da) | 2017-03-15 | 2022-04-11 | Modernatx Inc | Krystalformer af aminolipider |
WO2018170260A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus respiratoire syncytial |
SI3596041T1 (sl) * | 2017-03-15 | 2023-02-28 | Modernatx, Inc. | Spojina in sestavki za intracelično dostavljanje terapevtskih sredstev |
WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
EP3601576A1 (fr) | 2017-03-24 | 2020-02-05 | CureVac AG | Acides nucléiques codant pour des protéines associées à crispr et leurs utilisations |
EP3607074A4 (fr) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
EP3638215A4 (fr) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | Formulations d'arn |
MA49922A (fr) | 2017-08-18 | 2021-06-02 | Modernatx Inc | Procédés pour analyse par clhp |
US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
WO2019055807A1 (fr) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Vaccins à arn contre le virus zika |
CA3085784A1 (fr) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Circuit d'attaque et regulateur de transducteur acoustique |
US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
EP3921334A1 (fr) | 2019-02-08 | 2021-12-15 | Krystal Biotech, Inc. | Compositions et méthodes d'administration de polypeptides cftr |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
KR20210142636A (ko) | 2019-02-20 | 2021-11-25 | 모더나티엑스, 인크. | 공동-전사 캡핑을 위한 rna 폴리머라제 변이체 |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
EP4031524A1 (fr) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Composés lipidiques de queue ramifiés et compositions pour l'administration intracellulaire d'agents thérapeutiques |
WO2021204179A1 (fr) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Vaccins à base d'acide nucléique pour coronavirus |
MX2022012630A (es) | 2020-04-09 | 2022-11-07 | Suzhou Abogen Biosciences Co Ltd | Composicion de nanoparticulas lipidicas. |
TW202206096A (zh) | 2020-04-22 | 2022-02-16 | 德商拜恩迪克Rna製藥有限公司 | 冠狀病毒疫苗 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
AU2021377895A1 (en) * | 2020-11-13 | 2023-06-15 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
WO2022212766A2 (fr) * | 2021-03-31 | 2022-10-06 | Hunterian Medicine Llc | Promoteurs compacts pour l'expression génique |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS63964B1 (sr) | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
AU2007308130A1 (en) | 2006-10-12 | 2008-04-17 | Copernicus Therapeutics Inc. | Codon optimized CFTR |
WO2009030254A1 (fr) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes d'arn et de peptides cationiques pour transfection et immunostimulation |
CA3077990A1 (fr) | 2009-12-01 | 2011-06-09 | Translate Bio, Inc. | Administration d'arnm pour l'augmentation des proteines et des enzymes dans des maladies genetiques humaines |
US10086043B2 (en) | 2011-04-03 | 2018-10-02 | The General Hospital Corporation | Efficient protein expression in vivo using modified RNA (MOD-RNA) |
CA3198966A1 (fr) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Lipides clivables |
KR20200084048A (ko) | 2011-06-08 | 2020-07-09 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
MX367842B (es) | 2012-02-07 | 2019-09-09 | Global Bio Therapeutics Inc | Método compartimentado de administración de ácidos nucleicos y composiciones y usos del mismo. |
EP2830596B1 (fr) | 2012-03-29 | 2020-12-30 | Translate Bio, Inc. | Nanoparticules neutres dérivées de lipides |
CN108949772A (zh) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP2834259A4 (fr) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | Polynucléotides modifiés |
US20140275229A1 (en) | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
EP2858679B2 (fr) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Administration pulmonaire d'arnm à des cellules cibles autres que pulmonaires |
KR20150020288A (ko) | 2012-06-08 | 2015-02-25 | 에트리스 게엠베하 | 메신저 rna의 폐전달 |
ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
BR112015022868B1 (pt) * | 2013-03-14 | 2023-05-16 | Ethris Gmbh | Composições de mrna de cftr e usos e métodos relacionados |
JP6567494B2 (ja) | 2013-03-14 | 2019-08-28 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 4’−チオ−修飾ヌクレオチドを有するリボ核酸及び関連方法 |
EA201690576A1 (ru) * | 2013-10-22 | 2016-10-31 | Шир Хьюман Дженетик Терапис, Инк. | Липидные композиции для доставки матричной рнк |
JP6594421B2 (ja) * | 2014-06-25 | 2019-10-23 | アクイタス セラピューティクス インコーポレイテッド | 核酸の送達のための新規脂質および脂質ナノ粒子製剤 |
CN114146063A (zh) | 2014-07-02 | 2022-03-08 | 川斯勒佰尔公司 | 信使rna的包封 |
CA2955375A1 (fr) * | 2014-07-17 | 2016-01-21 | Modernatx, Inc. | Modifications de terminal de polynucleotides |
WO2016118724A1 (fr) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Compositions de nanoparticules lipidiques |
HUE057613T2 (hu) * | 2015-09-17 | 2022-05-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
DK3368507T3 (da) | 2015-10-28 | 2023-02-27 | Acuitas Therapeutics Inc | Nye lipider og lipidnanopartikelformuleringer til frigivelse af nukleinsyrer |
WO2017106799A1 (fr) | 2015-12-17 | 2017-06-22 | Modernatx, Inc. | Polynucléotides codant pour la méthylmalonyl-coa mutase |
US11377656B2 (en) | 2016-03-10 | 2022-07-05 | Novartis Ag | Chemically modified messenger RNA's |
EP3452101A2 (fr) | 2016-05-04 | 2019-03-13 | CureVac AG | Arn codant pour une protéine thérapeutique |
MA45032A (fr) | 2016-05-18 | 2019-03-27 | Fundacion Para La Investig Medica Aplicada | Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë |
US20190390181A1 (en) | 2016-05-18 | 2019-12-26 | Modernatx, Inc. | Polynucleotides Encoding Lipoprotein Lipase for the Treatment of Hyperlipidemia |
US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
JP7210287B2 (ja) | 2016-05-18 | 2023-01-23 | モダーナティエックス・インコーポレイテッド | Ii型シトルリン血症の治療のためのシトリンをコードするポリヌクレオチド |
MA45041A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1 |
CA3043033A1 (fr) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Formulation de nanoparticules lipidiques a base de glace amelioree pour l'administration de l'arnm |
EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
EP3398963B1 (fr) | 2017-05-04 | 2021-09-29 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Arnm chimiquement modifié pour une utilisation dans le traitement d'une maladie associée au gène cftr |
IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr |
US20210378977A1 (en) | 2018-07-23 | 2021-12-09 | Translate Bio, Inc. | Dry Powder Formulations for Messenger RNA |
MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
EP3908257A4 (fr) | 2019-01-08 | 2022-11-09 | Asklepios Biopharmaceutical, Inc. | Procédé de traitement de la fibrose kystique |
WO2021021988A1 (fr) | 2019-07-30 | 2021-02-04 | Translate Bio, Inc. | Traitement de la fibrose kystique par administration d'arnm nébulisé codant pour la cftr |
EP4031662A1 (fr) | 2019-09-20 | 2022-07-27 | Translate Bio, Inc. | Arnm codant pour cftr modifiée |
EP4093437A4 (fr) | 2020-01-22 | 2024-07-17 | Engene Inc | Expression localisée d'acides nucléiques thérapeutiques dans des cellules épithéliales pulmonaires |
BR112022021918A2 (pt) | 2020-04-27 | 2023-03-14 | Univ Iowa Res Found | Composições e métodos para o tratamento de fibrose cística |
US20220023442A1 (en) | 2020-05-01 | 2022-01-27 | Arcturus Therapeutics, Inc. | Nucleic acids and methods of treatment for cystic fibrosis |
EP4146342A1 (fr) | 2020-05-07 | 2023-03-15 | Translate Bio, Inc. | Compositions améliorées de thérapie par arnm de la cftr |
EP4240326A1 (fr) | 2020-11-09 | 2023-09-13 | Translate Bio, Inc. | Compositions améliorées pour l'administration d'arnm à optimisation des codons |
AU2021377895A1 (en) | 2020-11-13 | 2023-06-15 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
-
2017
- 2017-05-18 EP EP17800209.3A patent/EP3458108A4/fr active Pending
- 2017-05-18 WO PCT/US2017/033419 patent/WO2017201347A1/fr unknown
- 2017-05-18 US US16/302,370 patent/US11801227B2/en active Active
- 2017-05-18 MA MA045053A patent/MA45053A/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20190298658A1 (en) | 2019-10-03 |
WO2017201347A1 (fr) | 2017-11-23 |
EP3458108A4 (fr) | 2020-04-22 |
US11801227B2 (en) | 2023-10-31 |
EP3458108A1 (fr) | 2019-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45053A (fr) | Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique | |
MA54649A (fr) | Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique | |
MA45032A (fr) | Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë | |
MA45036A (fr) | Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2 | |
IL261987B (en) | Modulators of transmembrane conductance regulation in cystic fibrosis | |
MA49631A (fr) | Méthodes de traitement de la fibrose kystique | |
IL275049A (en) | Processes for preparing modulators to regulate cystic fibrosis transmembrane conductance | |
MA54105A (fr) | Méthodes de traitement de la fibrose kystique | |
MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
MA47558A (fr) | Traitement de la fibrose | |
DK3880197T3 (da) | Fremgangsmåder til behandling for cystisk fibrose | |
HK1243623A1 (zh) | 按摩器 | |
BR112017014213A2 (pt) | moduladores de ciclopropanocarboxamida do regulador da condutância transmembrana da fibrose cística. | |
EP3725273C0 (fr) | Appareil d'aide au mouvement | |
IL274763B1 (en) | Methods for making cystic fibrosis transmembrane conductance modulator modulators | |
DK3538766T3 (da) | Excentersnekkepumpe | |
SG11201707721VA (en) | Massaging apparatus | |
GB2556425B (en) | Eccentric screw pump | |
MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
HK1253917A1 (zh) | 按摩器 | |
MA50801A (fr) | Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie | |
FR3059015B1 (fr) | Appareil de repassage | |
PL3449128T3 (pl) | Pompa śrubowa jednowirnikowa | |
MA41094A (fr) | Procédés de traitement de troubles rénaux | |
DE112017003245A5 (de) | Wellness-Pantolette mit skalierbarer Akupressurwirkung |